Skip to content
A 3D model of the daraxonrasib molecule, shown as colored balls and sticks

Health

Pancreatic cancer pill daraxonrasib plus chemo shrank tumors in most early-trial patients

The results beat past chemo-only trials, but with no chemo-only group to compare, proof that it extends life waits on a 2028 trial.

Published 6 min read

A model of the daraxonrasib molecule, shaped as it is when it binds RAS, the cancer-driving protein the pill is built to switch off. Image: Jovan.gec / Wikimedia Commons / CC BY-SA 4.0

Who covered this

What these mean

The short version

  • A daily pill, daraxonrasib, plus standard chemotherapy shrank tumors in about 6 in 10 of 61 people with newly diagnosed pancreatic cancer that had spread.
  • Patients typically live under a year on chemo alone, but the trial was small, paid for by the drugmaker and had no chemo-only group.
  • A 900-patient trial that does compare the two is under way, with its main results expected around 2028.
Documents in this story · 3
  • ReleaseMetastatic pancreatic cancer responds well to initial treatmentEORTC-NCI-AACR Symposium · Press release · Nov. 20Open Archived
  • RecordFDA approves daraxonrasib for metastatic pancreatic adenocarcinomaFDA · Web page · Aug. 26Open Archived
  • RecordRASolute 303 (NCT07491445), updated Nov. 16ClinicalTrials.gov · Web pageOpen Archived

A daily pill called daraxonrasib, added to standard chemotherapy, shrank tumors in about 6 in 10 patients newly diagnosed with pancreatic cancer that had spread, according to early trial results presented Friday. In about 1 in 12, the tumors could no longer be seen on scans.

That matters because this is one of the deadliest cancers: once it has spread, only about 3% of patients live five years. But the trial was small, 61 patients, and every one of them got the new drug. Until a larger trial compares it with chemotherapy alone, no one can say whether it helps people live longer, or by how much.

Why it matters to you

The drug is already sold in the United States, but not for the use this trial tested. The Food and Drug Administration approved it on Aug. 26, under the brand name Rasonque, for adults with spread pancreatic cancer who were treated before, or who can't take multi-drug chemo. This trial gave it as a first treatment, a use the FDA has not approved.

That first-treatment question is now being tested head to head in a phase 3 trial called RASolute 303, which plans to enroll about 900 patients and is recruiting now. Patients and their doctors can look up its sites on the federal trial registry.

How the daraxonrasib pill did against pancreatic cancer

Dr. Wungki Park, a cancer doctor at Memorial Sloan Kettering Cancer Center in New York, presented the results on Friday, Nov. 20, at a cancer research meeting in Barcelona. The meeting is run by European and U.S. cancer groups, including the National Cancer Institute. The trial was funded by Revolution Medicines, the California company that makes the drug.

Patients took the pill once a day along with two chemotherapy drugs, gemcitabine and nab-paclitaxel, given by IV. After a typical follow-up of about 18 months, tumors had shrunk in about 61% of patients and stopped growing in about 90%. The typical patient went 12.8 months before the cancer grew again. A year after starting, about 77% were still alive.

The obvious yardstick is chemotherapy alone. In past trials, chemo shrank tumors in 23% to 42% of patients. The cancer usually started growing again after five or six months, and patients typically lived eight to 11 months. By that yardstick, the time before the cancer grew again was close to double.

Park went further in remarks The Guardian reported. "This is the closest to cure," he said, adding that he had never seen so many tumors disappear in patients whose cancer had spread.

Why the trial can't yet prove longer lives

The yardstick is borrowed. This was a phase 1/2 study, an early trial meant to find a safe dose and an early signal, and it had no control group. In the symposium's release, Park said "the results must be interpreted carefully" because no patients got chemotherapy alone. Without that comparison, doctors can't yet confirm how much better the combination does or whether it extends life, Fox News reported.

Side effects were mostly the kind doctors know how to manage. The most common were rash, diarrhea, tiredness and low blood counts from chemo, and about 5% of patients stopped because of side effects tied to the pill. The New York Post reported that skin problems hit 86% of patients in clinical trials of the drug, severe in 10%.

How the drug got to market first

Most pancreatic cancers are driven by a faulty gene called RAS, which tells cells to keep dividing. More than 90% of these cancers carry it. Until recently, drugs could not successfully target it. Dr. Nicholas Hornstein, a cancer doctor at Northwell's Lenox Hill Hospital, compared it to an accelerator that is stuck down, the New York Post reported. Daraxonrasib is designed to stop the active form of the RAS protein.

The pill first proved itself in patients who had already had chemo. In a larger trial called RASolute 302, about 500 such patients were split at random between the pill and standard chemo. Those on the pill lived a median of 13.2 months, against 6.7 on chemo, and the FDA approved it on those results.

the results must be interpreted carefully

Dr. Wungki Park, Memorial Sloan Kettering, in the symposium's release, Nov. 20 (EORTC-NCI-AACR Symposium)

That history explains why this week's reports split on whether the drug is approved or experimental. Both are partly right: it is approved for later treatment, and still being tested as a first one.

What we don't know yet

No one knows yet whether the pill helps patients live longer when they take it from the start. RASolute 303 is built to answer that, comparing the pill alone, the pill with chemo, and chemo alone. Its main results are expected around April 2028, by the registry's estimate.

It is also unclear how long the tumors that vanished will stay gone. Some patients' cancer had not come back by the end of follow-up, and longer studies will have to show whether any stay in remission. Whether the pill works in other cancers driven by RAS, such as some lung and bowel cancers, will take separate trials.

Where experts disagree

Where experts agree

The experts quoted this week agree the results are strong and early. Cancer Research UK, a British cancer charity, called them "the biggest leap forward in decades" for pancreatic cancer patients, while saying more trials are needed. Prof. Elena Garralda, who chairs the meeting and was not involved in the study, said the combination could improve how long patients live.

What's still debated

The open point is the word "cure." Park reached for it, while doctors quoted by the BBC said the results should not be seen as one. Dr. Sam Godfrey of Cancer Research UK told the BBC that cancer can come back even when scans are clear, so patients can't know they are free of it until more time passes.

How coverage differs

Only Fox News told its readers that the drugmaker paid for the trial and that no patient got chemo alone for comparison. Three other outlets said the pill was already approved, without saying for which patients.

If you read the left 1 of 13 outlets

You got the hope, and the hedges.

If you read the center 2 of 9 outlets

You heard it was approved, with gaps.

If you read the right 3 of 12 outlets

You read the limits, from Fox.

Sources

This article was produced by AI under our Editorial Standards. Corrections are reviewed before they go live.

Challenge this article

How coverage differs

Free with a Fair Witness account

See how left, center and right covered this story

A free account shows where the coverage agrees and where it splits, what each side played up and played down, and, when one side's outlets missed a story, who missed it.

Share this story

Challenge this article

Found a factual error? Send us published evidence. We review every submission and correct errors in public.

Keep reading

The newest stories in Health, then the rest of the site.

Newest · Health

Edge of Frame · Left

Judge approves Bayer's $7.25 billion Roundup settlement over cancer claims

The deal pays lymphoma patients over as long as 21 years and binds many who could fall ill later, after the Supreme Court weakened such lawsuits.

· 7 min read

A generic weed killer made with glyphosate, the same active ingredient as Roundup, set out with marking dye and a sprayer. Photo, Oct. 2023: Slknight / Wikimedia Commons / CC BY-SA 4.0

Latest

New stories and updates, newest first. Times are Eastern.

All updates
  1. Nov 22

    12:13 AMTop story U.S.

    ICE arrests two passengers on a Seattle airport jet bridge as they board a flight

    Washington's governor said he believes the masked officers broke a new state law, but that law's only penalty is a lawsuit by the people detained.

  2. Nov 21

    6:12 PMNew Economy

    Trump says he would work with Democrats on a 10% credit card interest rate cap

    The president and Sen. Elizabeth Warren now back a cap that banks and some Republican senators oppose, and no bill has moved yet.

  3. Nov 21

    5:19 PMUpdated Health

    US loses measles elimination status after 26 years, PAHO says

    The finding that measles spreads here again means the U.S. must now stop the spread for a full year to win the status back.

    Spin Meter: how each side framed it · 4/5
  4. Nov 21

    5:17 PMUpdated World

    Mexico captures 'El Chapo Isidro,' an FBI Ten Most Wanted fugitive, in Sinaloa raid

    U.S. prosecutors charged him in 2012, and Mexico has not yet said whether it will send him north to face those charges.

  5. Nov 21

    2:55 PMUpdated U.S.

    House Democrats seek Cantor Fitzgerald's Nvidia records in Lutnick probe

    The letter shows how the House's incoming Democratic chairs plan to test whether Lutnick's handling of Megaspeed was shaped by his family firm's Nvidia stake.

  6. Nov 21

    11:50 PMUpdated U.S.

    Trump orders federal contractors to check with White House before answering Congress

    The order gives the White House a say in what companies doing government work tell Congress, weeks before Democrats take charge and start investigating.

  7. Nov 21

    11:14 PMUpdated Science

    COP31 climate talks run into overtime after draft drops fossil fuels

    Whether the year's climate deal names oil, gas and coal at all now rests on a consensus rule that lets one country block it.

    Out of Frame · Right

  8. Nov 21

    11:12 PMUpdated Science

    BepiColombo enters Mercury orbit, only the second mission to circle the planet

    After an eight-year trip and a year's delay, two orbiters are set to study a planet that only NASA had circled before.

  9. Nov 21

    8:52 PMUpdated U.S.

    Storm that flooded Florida heads up the East Coast as Thanksgiving week nears

    Wind, rain and coastal flooding could reach the Carolinas Saturday and New England by Sunday night, and forecasters see another East Coast storm around Thanksgiving.

  10. Nov 21

    8:37 PMUpdated U.S.

    Cornyn blocks Elliot Gaiser, Trump's pick for a Dallas federal court seat

    A Texas senator's veto can stop a lifetime judgeship, and Republicans have until Jan. 3 to fill the seat before Democrats run the Senate.

  11. Nov 21

    8:36 PMUpdated World

    Russian missile crashes in Poland as strikes hit three Kyiv bridges

    Poland called the crash a likely intentional provocation during allied drills, and NATO's treaty leaves each ally to decide how to respond.

    Edge of Frame · Right

  12. Nov 21

    8:19 PMUpdated Technology

    FBI investigating apparent breach of its national crime database, CNN and NBC report

    Police across the country run warrant and gun checks on the system, and it is the second federal breach reported in a day.

  13. Nov 21

    8:18 PMUpdated U.S.

    Katie Zacharia faces California State Bar investigation over lawyer claims

    The case tests whether California's law making it a crime to claim you can practice law without a license reaches a TV commentator.

The Fair Witness Daily

Get each morning's Spin Meter in your inbox

The Daily leads with the Spin Meter, then the day's explainers. A free account also unlocks every Spin Meter on the site.

Check your inbox to confirm your subscription.

Free. Unsubscribe anytime. Already a member? Sign in